Tag: Radiation
Radiotherapy for Prostate Cancer Adjusted During COVID-19
Telemedicine consults recommended; treatment can be avoided, delayed in low, intermediate-risk disease
10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
10-year cumulative incidence of biochemical and/or clinical disease failure no different with C-, H-IMRT
Per-Capita Medical Radiation Exposure Down in United States
2006 to 2016 saw drop in annual individual effective dose from diagnostic, interventional procedures
Thoracic Radiation May Increase Fatigue, Dyspnea in Short Term
In patients with lung cancer or lymphoma, increase in heart dose tied to decrease in physical activity
Radiologist Workforce Becoming Increasingly Subspecialized
Increased subspecialization seen across cohorts defined by gender, years in practice, practice size
Reirradiation Rarely Required in Focal RT for Multiple Myeloma
For biologically effective dose ≤28 Gy10, small but significant increase seen in reirradiation rates
Intensity-Modulated Radiation Charges for Prostate Cancer Vary
Mean charge for standard 28-fraction was $111,728.80, 10.1 times the price paid by Medicare
Adverse Events Decreased With Proton Chemoradiotherapy
Relative risks lower for 90-day adverse events of at least grade 3 and 2 compared with photon therapy
ASTRO Issues Recs for Radiation Tx of Basal, Squamous Cell Carcinoma
RT recommended as primary treatment for BCC, cSCC patients who are not surgical candidates
RT for DCIS Ups Mortality Risk in Invasive Second Breast Cancer
Rates of mortality for invasive second breast cancer higher in those with prior radiotherapy for DCIS
